Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Carrasco Valiente

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|September 14, 2012
Extracorporeal shock wave lithotripsy for distal ureteral calculi: improved efficacy using low frequencyFrancisco Jose Anglada-Curado, Pablo Campos-Hernández, Julia Carrasco-Valiente, et al.
Urology|November 15, 2016
European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical SignificanceEnrique Gómez-Gómez, Julia Carrasco-Valiente, Ana Blanca-Pedregosa, et al.
British Journal of Cancer|May 17, 2019
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancerMaria Frantzi, Enrique Gomez Gomez, Ana Blanca Pedregosa, et al.
Journal of Cellular and Molecular Medicine|November 20, 2018
Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancerEnrique Gómez-Gómez, Julia Carrasco-Valiente, Juan Pablo Campos-Hernández, et al.
Cancers|February 25, 2023
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal ExaminationMaria Frantzi, Zoran Culig, Isabel Heidegger, et al.
BMJ Open|November 15, 2019
Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mLEnrique Gomez Gomez, Juan José Salamanca Bustos, Julia Carrasco Valiente, et al.
Prostate Cancer and Prostatic Diseases|May 6, 2020
Telomere-based risk models for the early diagnosis of clinically significant prostate cancerJuan Manuel Rubio Galisteo, Luis Fernández, Enrique Gómez Gómez, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|November 11, 2024
Validation of a Urine-Based Proteomics Test to Predict Clinically Significant Prostate Cancer: Complementing mpMRI PathwayMaria Frantzi, Ana C Morillo, Guillermo Lendinez, et al.
The Journal of Clinical Endocrinology and Metabolism|July 13, 2021
In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate CancerJuan M Jiménez-Vacas, Antonio J Montero-Hidalgo, Enrique Gómez-Gómez, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 6, 2025
miR-191-5p: A tumour suppressor miRNA and a personalized biomarker and potential therapeutic tool connecting prostate cancer and obesityFrancisco Porcel-Pastrana, Antonio J Montero-Hidalgo, Vicente Herrero-Aguayo, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
International Journal of Urology : Official Journal of the Japanese Urological Association|September 14, 2012
Extracorporeal shock wave lithotripsy for distal ureteral calculi: improved efficacy using low frequencyFrancisco Jose Anglada-Curado, Pablo Campos-Hernández, Julia Carrasco-Valiente, et al.
Urology|November 15, 2016
European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical SignificanceEnrique Gómez-Gómez, Julia Carrasco-Valiente, Ana Blanca-Pedregosa, et al.
British Journal of Cancer|May 17, 2019
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancerMaria Frantzi, Enrique Gomez Gomez, Ana Blanca Pedregosa, et al.
Journal of Cellular and Molecular Medicine|November 20, 2018
Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancerEnrique Gómez-Gómez, Julia Carrasco-Valiente, Juan Pablo Campos-Hernández, et al.
Cancers|February 25, 2023
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal ExaminationMaria Frantzi, Zoran Culig, Isabel Heidegger, et al.
BMJ Open|November 15, 2019
Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mLEnrique Gomez Gomez, Juan José Salamanca Bustos, Julia Carrasco Valiente, et al.
Prostate Cancer and Prostatic Diseases|May 6, 2020
Telomere-based risk models for the early diagnosis of clinically significant prostate cancerJuan Manuel Rubio Galisteo, Luis Fernández, Enrique Gómez Gómez, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|November 11, 2024
Validation of a Urine-Based Proteomics Test to Predict Clinically Significant Prostate Cancer: Complementing mpMRI PathwayMaria Frantzi, Ana C Morillo, Guillermo Lendinez, et al.
The Journal of Clinical Endocrinology and Metabolism|July 13, 2021
In1-Ghrelin Splicing Variant as a Key Element in the Pathophysiological Association Between Obesity and Prostate CancerJuan M Jiménez-Vacas, Antonio J Montero-Hidalgo, Enrique Gómez-Gómez, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 6, 2025
miR-191-5p: A tumour suppressor miRNA and a personalized biomarker and potential therapeutic tool connecting prostate cancer and obesityFrancisco Porcel-Pastrana, Antonio J Montero-Hidalgo, Vicente Herrero-Aguayo, et al.
Pageof 3